Product image of Maymetsi (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Maymetsi

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a Biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when used in combination with diet, exercise, and other antidiabetic agents.

GNH India supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable logistics for global distribution to meet patient needs.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maymetsi combines metformin and sitagliptin to improve glycemic control in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves blood glucose levels when added to diet and exercise.
  • Inadequate control on metformin alone: provides additional glucose‑lowering effect.
  • Combination therapy with other antidiabetics: enhances overall glycemic management.

How It Works

  • Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to higher endogenous incretin levels that stimulate glucose‑dependent insulin secretion and suppress glucagon release, together producing improved blood glucose regulation.

Side Effects

Adverse reactions may occur with oral antidiabetic combinations.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: increased stool frequency, often transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild persistent headache.
  • Upper respiratory tract infection: nasopharyngitis symptoms.
  • Metallic taste: altered taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Severe skin reactions: such as Stevens‑Johnson syndrome.
  • Hepatic dysfunction: elevated liver enzymes.
  • Anaphylaxis: rare allergic reaction requiring immediate medical attention.

Precautions & Warnings

Use of Maymetsi requires careful clinical assessment and monitoring.

  • Renal function: assess baseline and monitor periodically to avoid accumulation.
  • Lactic acidosis risk: avoid in patients with severe renal impairment or conditions predisposing to hypoxia.
  • Pregnancy: consider only if potential benefit justifies potential risk to the fetus.
  • Hypersensitivity: discontinue if rash, angioedema, or other allergic signs develop.
  • Drug interactions: review concomitant medications for possible additive effects.
  • Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Maymetsi may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate acute renal failure when combined with metformin.
  • Strong CYP2C9 inhibitors: can increase plasma levels of sitagliptin.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: may enhance risk of hypoglycemia.
  • Diuretics: can affect renal clearance of metformin.
  • ACE inhibitors or ARBs: may increase risk of renal impairment.
  • Alcohol: can potentiate metformin‑associated lactic acidosis.
  • Anticoagulants: may require dose adjustment due to altered glycemic control.

Frequently Asked Questions

Maymetsi is an oral antidiabetic medication that combines metformin hydrochloride and sitagliptin. It is used to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, increasing incretin hormones that stimulate insulin release and suppress glucagon. Together they lower blood glucose through complementary mechanisms.

The specific dose of Maymetsi is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Maymetsi in pregnancy or lactation has not been fully established. It should only be used if the potential benefits outweigh the possible risks, and the decision must be made by a qualified healthcare provider after careful evaluation.

To order Maymetsi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maymetsi offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitizing and incretin‑enhancing effects in a single tablet. This can simplify regimens compared with taking separate agents, and may achieve better glycemic control than metformin alone while avoiding the injectable route required for some alternatives.

Maymetsi tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Maymetsi is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and pancreatitis, which can occur with sitagliptin. Patients should be aware of symptoms such as severe abdominal pain, unexplained fatigue, or rapid breathing and seek immediate medical attention if they arise.

Maymetsi is contraindicated in patients with severe renal impairment, known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT